Skip to main content

Articles By Janet Pope, MD, MPH, FRCPC

Pope

Lessons Learned from a Lupus Registry: Two sides of one coin?

I want to talk about a large Canadian registry that sometimes doesn't get as much airtime. Our group is called CaNIOS: Canadian Network for Improved Outcomes in SLE. We've enrolled more than a thousand patients, seen at least annually and some for many years. These patients are incident or prevalent and they've consented to be in the database. So what have we learned looking at kid-onset versus adult-onset lupus?

Read Article
question marks

Emulation trials in SLE: Real or Fake?

Recently a landmark paper was published in A&R studying the results of an emulation trial on SGLT2i (sodium-glucose co-transporter 2 inhibitors) showing benefit in SLE patients with diabetes mellitus (DM), for both renal protection and reducing cardiovascular events, using data from an American large insurance claim database. My colleagues and I were able to write an editorial on this paper and describe emulation trials.

Read Article
question-mark-1872634_640.jpg

ICYMI: JAKi in inflammatory myositis?

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
question mark

ICYMI: Are Emulation Trials a Fantasy?

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
question-mark-1872634_640.jpg

JAKi in inflammatory myositis?

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
question mark

Are Emulation Trials a Fantasy?

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
JAK Janus

New indications for JAK inhibitors

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
older woman with clasped hands

ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do!

Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.

Read Article
puzzle.RA_.jpg

Here’s what will change my practice in Rheumatoid Arthritis

Here's what I learned at ACR23 that will change the way I practice in rheumatoid arthritis. 

Read Article
×